NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the resignation of Mr. Bing Wang from his position of the Company with immediate effect, and the concomitant appointment of Mr. Arthur Stril as interim Chief Financial Officer, replacing Mr. Bing Wang. Mr. Stril joined Cellectis in 2018 as Vice President, Corporate Development, and ...

Title of each class American Depositary Shares, each representing one American Depositary Shares, each representing one Ordinary shares, nominal value €0.05 per share* Nasdaq Global Market* * Not for trading, but only in connection with the registration of the American Depositary Shares. Securities registered pursuant to Section 12(g) of the Act. None 40 125 Washington, D.C. 20549 FORM 20-F France (Jurisdiction of incorporation or organization) Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris, France (Ad ...

•   Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting •   Execution of strategic collaboration and investment agreements with AstraZeneca •   Cécile Chartier, Ph.D., appointed as a director of the Cellectis' Board of Directors •   Drawdown of the second tranche of €15 million under the credit facility agreement entered into with the European Investment Bank (EIB) •   Cash position of $156 milli ...

This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will present first ...

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage. This approach could unlock new therapeutic avenues for ...

Cellectis SA (NASDAQ:CLLS) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-founder, CEO& Director Mark Frattini - Chief Medical Officer Bing Wang - CFO Conference Call Participants Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird & Co. Silvan Tuerkcan - JMP Securities Whitney Watson - Goldman Sachs Operator Good morning, everyone, and welcome to the Cellectis Third Quarter 2023 Earnings ...

Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash and cash equivalents are held in bank accounts, money market funds, and fixed bank deposits, in each case primarily in France. The portion of cash and cash equivalents denominated in U.S. dollars is $44.5 million as of September 30, 2023. Historical Changes in Cash Flows The table below summarizes our sources and uses of cash For the ...

Exhibit 99.1 The unaudited condensed Consolidated Financial Statements for the three- and six-month periods ended June 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34")– Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to "$" and "U.S. dollars" mean U.S. dollars and all references to "€" and "e ...

Cellectis SA (NASDAQ:CLLS) Q2 2023 Earnings Conference Call August 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-Founder, CEO & Director Mark Frattini - SVP, Clinical Sciences & Chief Medical Officer Bing Wang - CFO Conference Call Participants Yigal Nochomovitz - Citigroup Gena Wang - Barclays Bank Yanan Zhu - Wells Fargo Anoumid Vaziri - Goldman Sachs Group Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird Silvan Tuerkcan - J ...

Cellectis SA (NASDAQ:CLLS) Q1 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-Founder, CEO & Director Mark Frattini - SVP, Clinical Sciences & Chief Medical Officer Bing Wang - CFO Conference Call Participants Gena Wang - Barclays Bank Yigal Nochomovitz - Citigroup Anoumid Vaziri - Goldman Sachs Group Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird & Co. Ingrid Gafanhao - Kempen Silvan Tuerkcan ...